Montlhéry, France

Alain Civier

This inventor holds 1 USPTO granted patent. Top assignee: Agence Nationale De Valorisation De La Recherche. Active years: 1984.


% Patents Active = 100.0

Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 20(Granted Patents)


Company Filing History:


Years Active: 1984

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Alain Civier

Introduction

Alain Civier is a notable inventor based in Montlhéry, France. He has made significant contributions to the field of chemistry, particularly in the development of novel compounds that have potential applications in medical treatments.

Latest Patents

Civier holds a patent for Pyrido (4,3-B) carbazoles substituted in the 1 position by a polyamine. This innovative compound corresponds to a specific general formula, where R₁ is a Y–(CH₂)ₙ–NR₄R₅ group. In this formula, Y can represent a single bond or a specific group, while R₄ and R₅ can be hydrogen or an alkyl radical. The compound is particularly useful for the treatment of leukemias, showcasing Civier's commitment to advancing medical science. He has 1 patent to his name.

Career Highlights

Civier is associated with the Agence Nationale De Valorisation De La Recherche, where he continues to work on innovative projects. His research focuses on developing compounds that can lead to breakthroughs in medical treatments.

Collaborations

Throughout his career, Civier has collaborated with esteemed colleagues, including Claire Ducrocq and Francoise Wendling. These partnerships have contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Alain Civier's work exemplifies the spirit of innovation in the field of chemistry. His contributions, particularly in the development of compounds for leukemia treatment, highlight the importance of research and collaboration in advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…